参考文献:[1]王天歌, 陆洁莉, 毕宇芳, 等.中国糖尿病持续攀升新解:中年肥胖相关胰岛素抵抗成为主要威胁 [J] .中华内分泌代谢杂志,2020,36(3): 198-200.[2]Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetologia,2012,55(6):1577-1596.[3]Nuffer W, Guesnier A, Trujillo JM. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products[J]. Ther Adv Endocrinol Metab, 2018,9(3):69-79.[4]Anderson SL, Trujillo JM. Basal insulin use with GLP-1 receptor agonists[J]. Diabetes Spectr,2016,29(3):152-160.[5]Kalra S, Baruah MP, Sahay RK, et al. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future[J]. Indian J Endocrinol Metab, 2016,20(2):254-267. [6]Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2012,8(12):728-742.[7]Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies[J]. Ther Adv Endocrinol Metab, 2015,6(1):19-28.[8]Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016,375(4):311-322.[9]Greco EV, Russo G, Giandalia A, et al. GLP-1 receptor agonists and kidney protection[J]. Medicina (Kaunas), 2019,55(6):233.[10]Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis[J]. Diabetes Res Clin Pract, 2015,110(1):26-37.[11]Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis[J]. Clin Ther, 2015,37(1):225-241.e8.[12]Pei Y, Agner BR, Luo B, et al. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin[J]. Diabetes Obes Metab, 2021,23(12):2687-2696.[13]Kaku K, Araki E, Tanizawa Y, et al. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial[J]. Diabetes Obes Metab, 2019, 21 (12): 2674 - 2683. “此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场”